摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(4R,9aS)-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one | 937816-17-6

中文名称
——
中文别名
——
英文名称
(4R,9aS)-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one
英文别名
(4R,9aS)-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6(1H)-one;(4R,9aS)-4-(3,4,5-trifluorophenyl)-3,4,7,8,9,9a-hexahydro-1H-pyrido[2,1-c][1,4]oxazin-6-one
(4R,9aS)-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one化学式
CAS
937816-17-6
化学式
C14H14F3NO2
mdl
——
分子量
285.266
InChiKey
OAOYQXITIDWHKG-CABZTGNLSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    390.8±42.0 °C(Predicted)
  • 密度:
    1.36±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    20
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    29.5
  • 氢给体数:
    0
  • 氢受体数:
    5

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Prodrug of cinnamide compound
    摘要:
    本发明提供了一种桂皮酰胺化合物的最适宜的前药。该前药由式(I)表示,其中R a 和R b 分别表示C1-6烷基或类似物;X a 表示甲氧基或氟原子;Y表示磷酸酯基团或类似物;A表示环内酰胺衍生物。
    公开号:
    US20090048213A1
  • 作为产物:
    描述:
    (4R,9aS)-4-(3,4,5-trifluorophenyl)-3,4,7,9a-tetrahydro-1H-pyrido[2,1-c][1,4]oxazin-6-one 在 platinum(IV) oxide 氢气 作用下, 以 甲醇 为溶剂, 反应 2.0h, 生成 (4R,9aS)-4-(3,4,5-trifluorophenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one
    参考文献:
    名称:
    Prodrug of cinnamide compound
    摘要:
    本发明提供了一种桂皮酰胺化合物的最适宜的前药。该前药由式(I)表示,其中R a 和R b 分别表示C1-6烷基或类似物;X a 表示甲氧基或氟原子;Y表示磷酸酯基团或类似物;A表示环内酰胺衍生物。
    公开号:
    US20090048213A1
点击查看最新优质反应信息

文献信息

  • PROCESS FOR PRODUCTION OF 4-(SUBSTITUTED PHENYL)HEXAHYDROPYRIDOÝ2,1-C¨Ý1,4¨OXAZIN-6-ONE
    申请人:Eisai R&D Management Co., Ltd.
    公开号:EP2226325A1
    公开(公告)日:2010-09-08
    4-(Substituted phenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one represented by formula (I) or a salt thereof is useful as an intermediate for the production of a bicyclic cinnamide compound which is an Aβ production inhibitor. 4-(Substituted phenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one or the salt thereof can be produced in an industrially advantageous manner by subjecting a compound represented by formula (II) or a salt thereof to an intramolecular condensation reaction.
    公式(I)表示的4-(取代苯基)六氢吡啶并[2,1-c][1,4]噁唑啉-6-酮或其盐可用作生产双环丁酰胺化合物的中间体,该化合物是Aβ产生抑制剂。通过将公式(II)表示的化合物或其盐经历分子内缩合反应,可以以工业上有利的方式生产4-(取代苯基)六氢吡啶并[2,1-c][1,4]噁唑啉-6-酮或其盐。
  • Two cyclic cinnamide compound
    申请人:Kimura Teiji
    公开号:US20070117839A1
    公开(公告)日:2007-05-24
    The present invention relates to a novel two cyclic cinnamide compound and a pharmaceutical agent comprising the compound as an active ingredient. The two cyclic cinnamide compound represented by the general formula (I): wherein represents a single bond or a double bond; Ar 1 represents a phenyl group or pyridinyl group that may be substituted with 1 to 3 substituents; R 1 and R 2 each represent a C1-6 alkyl group, a hydroxyl group, or the like; Z 1 represents a methylene group or vinylene group, which may be substituted with 1 or 2 substituents selected from Substituent Group A1, an oxygen atom, or an imino group that may be substituted with a substituent selected from Substituent Group A1; and p, q, and r each represent an integer of 0 to 2, which has an effect of reducing Aβ40 and Aβ42 production, and thus is particularly useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ such as Alzheimer's disease or Down's syndrome.
    本发明涉及一种新型的二环丙烯酰胺化合物和包含该化合物作为活性成分的药物。所述二环丙烯酰胺化合物由通式(I)表示:其中,表示单键或双键;Ar1表示苯基或吡啶基,可以被1至3个取代基取代;R1和R2分别表示C1-6烷基、羟基或类似物;Z1表示亚甲基或乙烯基,可以被从取代基A1中选择的1或2个取代基、氧原子或取代基A1选择的亚胺基取代;p、q和r分别表示0至2的整数,具有降低Aβ40和Aβ42生成的作用,因此特别适用于作为预防或治疗Aβ引起的神经退行性疾病,如阿尔茨海默病或唐氏综合症的药物。
  • PROCESS FOR PRODUCTION OF 4- (SUBSTITUTED PHENYL) HEXAHYDROPYRIDO [2,1-C] [1,4] OXAZIN-6-ONE
    申请人:Kayano Akio
    公开号:US20100280243A1
    公开(公告)日:2010-11-04
    4-(Substituted phenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one represented by formula (I) or a salt thereof is useful as an intermediate for the production of a bicyclic cinnamide compound which is an Aβ production inhibitor. 4-(Substituted phenyl)hexahydropyrido[2,1-c][1,4]oxazin-6-one or the salt thereof can be produced in an industrially advantageous manner by subjecting a compound represented by formula (II) or a salt thereof to an intramolecular condensation reaction.
    公式(I)表示的4-(取代苯基)六氢吡啶[2,1-c][1,4]噁唑-6-酮或其盐是生产双环丙烯酰胺化合物的中间体,该化合物是Aβ产生抑制剂。通过将公式(II)表示的化合物或其盐经历分子内缩合反应,可以以工业上优势的方式生产4-(取代苯基)六氢吡啶[2,1-c][1,4]噁唑-6-酮或其盐。
  • TWO CYCLIC CINNAMIDE COMPOUND
    申请人:Kimura Teiji
    公开号:US20090181945A1
    公开(公告)日:2009-07-16
    The present invention relates to a novel two cyclic cinnamide compound and a pharmaceutical agent comprising the compound as an active ingredient. The two cyclic cinnamide compound represented by the general formula (I): wherein represents a single bond or a double bond; Ar 1 represents a phenyl group or pyridinyl group that may be substituted with 1 to 3 substituents; R 1 and R 2 each represent a C1-6 alkyl group, a hydroxyl group, or the like; Z 1 represents a methylene group or vinylene group, which may be substituted with 1 or 2 substituents selected from Substituent Group A1, an oxygen atom, or an imino group that may be substituted with a substituent selected from Substituent Group A1; and p, q, and r each represent an integer of 0 to 2, which has an effect of reducing Aβ40 and Aβ42 production, and thus is particularly useful as a prophylactic or therapeutic agent for a neurodegenerative disease caused by Aβ such as Alzheimer's disease or Down's syndrome.
    本发明涉及一种新型的双环肉桂酰胺化合物和一种以该化合物为活性成分的药物制剂。该双环肉桂酰胺化合物由通式(I)表示:其中,表示单键或双键;Ar1表示苯基或吡啶基,可以用1至3个取代基取代;R1和R2各表示C1-6烷基、羟基或类似物;Z1表示亚甲基或乙烯基,可以用来自取代基A1的1或2个取代基、氧原子或可用取代基A1取代的亚胺基取代;p、q和r各表示0至2的整数,具有减少Aβ40和Aβ42产生的作用,因此特别适用于作为预防或治疗Aβ引起的神经退行性疾病,如阿尔茨海默病或唐氏综合症的药物制剂。
  • BICYCLIC CINNAMIDE COMPOUND
    申请人:Eisai R&D Management Co., Ltd.
    公开号:EP1953158A1
    公开(公告)日:2008-08-06
    A bicyclic cinnamide compound represented by the general formula (I): wherein ---- represents a single bond or a double bond; Ar1 represents a phenyl group or pyridinyl group optionally substituted by one to three substituents; R1 and R2 each represents a C1-6 alkyl group, a hydroxyl group, etc.; Z1 represents an optionally substituted methylene group or vinylene group, an oxygen atom, or an imino group optionally substituted by a Cl-6 alkyl group or a Cl-6 acyl group; and p, q, and r each is an integer of 0 to 2. It functions to reduce Aβ40 and Aβ42. It is hence useful especially as a prevention or remedy for neurodegenerative diseases of which Aβ is causative, such as Alzheimer's disease and Down's syndrome.
    由通式(I)代表的双环肉桂化合物: 其中 ---- 代表单键或双键;Ar1 代表任选被一至三个取代基取代的苯基或吡啶基;R1 和 R2 分别代表 C1-6 烷基、羟基等;Z1 代表任选被取代的亚甲基或亚乙烯基、氧原子或任选被 Cl-6 烷基或 Cl-6 丙烯酸基取代的亚氨基;p、q 和 r 分别为 0 至 2 的整数。 它具有降低 Aβ40 和 Aβ42 的功能。因此,它特别适用于预防或治疗 Aβ 导致的神经退行性疾病,如阿尔茨海默氏症和唐氏综合症。
查看更多

同类化合物

(4-甲基环戊-1-烯-1-基)(吗啉-4-基)甲酮 (2-肟基-氰基乙酸乙酯)-N,N-二甲基-吗啉基脲六氟磷酸酯 鲸蜡基乙基吗啉氮鎓乙基硫酸盐 马啉乙磺酸钾 预分散OTOS-80 顺式4-(氮杂环丁烷-3-基)-2,2-二甲基吗啉 顺式-N-亚硝基-2,6-二甲基吗啉 顺式-3,5-二甲基吗啉 顺-2,6-二甲基-4-(4-硝基苯基)吗啉 非屈酯 雷奈佐利二聚体 阿瑞杂质9 阿瑞吡坦磷的二卞酯 阿瑞吡坦杂质 阿瑞吡坦杂质 阿瑞吡坦 阿瑞吡坦 阿瑞匹坦非对映异构体2R3R1R 阿瑞匹坦杂质A异构体 阿瑞匹坦杂质54 阿瑞匹坦-M3代谢物 钾[2 - (吗啉- 4 -基)乙氧基]甲基三氟硼酸 邻苯二甲酸单吗啉 调节安 试剂2-(4-Morpholino)ethyl2-bromoisobutyrate 茂硫磷 苯甲腈,2-(4-吗啉基)-5-[1,4,5,6-四氢-4-(羟甲基)-6-羰基-3-哒嗪基]- 苯甲曲秦 苯甲吗啉酮 苯基2-(2-苯基吗啉-4-基)乙基碳酸酯盐酸盐 苯二甲吗啉一氢酒石酸盐 苯二甲吗啉 苯乙酮 O-(吗啉基羰基甲基)肟 芬美曲秦 芬布酯盐酸盐 芬布酯 脾脏酪氨酸激酶(SYK)抑制剂 脱氯利伐沙班 脱氟雷奈佐利 羟基1-(3-氯苯基)-2-[(1,1-二甲基乙基)氨基]-1-丙酮盐酸盐 福沙匹坦苄酯 福沙匹坦杂质26 福曲他明 碘化N-甲基丙基吗啉 碘化N-甲基,乙基吗啉 硝酸吗啉 盐酸吗啡啉-D8 甲基吗啉-2-羧酸甲酯2,2,2-三氟乙酸盐 甲基N-[3-(乙酰基氨基)-4-[(2-氰基-4,6-二硝基苯基)偶氮]苯基]-N-乙基-&#x3B2-丙氨酸酸酯 甲基4-吗啉二硫代甲酸酯